Loading…
CLGN
CollPlant Biotechnologies Ltd
NASDAQ· Healthcare· Biotechnology· CUSIP M2R51X116
$0.36+23.58%Price as of Aug 29, 18:43 UTC · updated once a day, after the close
Key metrics
- Market cap
- $6.77M
- P/E
- —
- Forward P/E
- —
- P/B
- 1.1x
- Dividend yield
- —
- Payout
- —
- EPS
- -$1.23
- ROE
- -151.99%
- Profit margin
- 0.00%
- Revenue growth
- -96.40%
- Beta
- 0.68
- 52-week high
- $3.18
- 52-week low
- $0.26
History
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Investors holding this
Major managers that reported this stock in their latest 13F.
Price over time
▼ -98.1% over 5Y.
today you would have $25.15▼ -97.5%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Indicators, year by year
The last 4 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Year-end price | $14.00 | $36.00 | $63.90 | $83.50 | |
| P/S | 438.2x | 75.6x | 800.7x | 66.8x | 3124.0x |
| P/B | 29.2x | 29.5x | 30.6x | 25.8x | 28.9x |
| EPS | -$0.94 | -$1.45 | -$0.62 | -$1.53 | |
| Profit margin | -1854.81% | -484.56% |
Others in the same sector
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| DRMADermata Therapeutics, Inc. | $1.34 | — | 1.5x | — | -183.89% | $6.64M |
| ACONAclarion, Inc. | $2.40 | — | 0.3x | — | -58.97% | $6.92M |
| BMRABiomerica Inc | $2.14 | — | 2.0x | — | -94.32% | $6.61M |
| VNRXVolitionrx Ltd | $0.45 |
About the company
CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on its recombinant human collagen (rhCollagen) that is produced using its proprietary technology. The company offers regenerative dermal and soft tissue fillers; 3D-bioprinted regenerative breast implants; Collage, a combinant human Collagen type I solution; VergenixSTR, a soft tissue matrix for the treatment of tendinopathy; and VergenixFG, a wound care product for the treatment of deep surgical incisions and deep wounds. It also provides rhcollagen-based commercial bioink for regenerative medicine applications, such as Collink.3D 50L, a bioink in powder form; Collink.3D 90, an rhCollagen-based bioink solution for use in various 3D bioprinting applications; and Collink.3D 50, an rhCollagen-based bioink product. The company has collaboration agreements with AbbVie; STEMCELL; the Advanced Regenerative Manufacturing Institute; Stratasys; and RegenMed Development Organization. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. CollPlant Biotechnologies Ltd. was founded in 2004 and is headquartered in Rehovot, Israel.
- 39
- Rehovot, Israel
Company description provided by Yahoo Finance.